Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Jung Young Shin"'
Autor:
Min-Young Kim, Jung-Young Shin, Jeong-Oh Kim, Kyoung-Hwa Son, Yeon Sil Kim, Chan Kwon Jung, Jin-Hyoung Kang
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-14 (2020)
Abstract Background Hypoxic tumors are known to be highly resistant to radiotherapy and cause poor prognosis in non-small cell lung cancer (NSCLC) patients. CKD-516, a novel vascular disrupting agent (VDA), mainly affects blood vessels in the central
Externí odkaz:
https://doaj.org/article/4378f3f5e1e8448784237686d3099f49
Publikováno v:
Anticancer Research. 41:4807-4820
Background/aim LY2835219 (LY), a novel CDK4/6 inhibitor, prevents cell proliferation through G1 arrest. Docetaxel (DTX) and paclitaxel (PTX) are cytotoxic drugs targeting tubulin-mediated apoptotic cell death via G2/M arrest. We evaluated the antitum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7892672ac64612b7c3c86f982e5794e2
https://doi.org/10.21873/anticanres.15296
https://doi.org/10.21873/anticanres.15296
Autor:
Jeong-Oh Kim, Jung-Young Shin, Min-Young Kim, Mi-Ran Lee, Seoree Kim, Hankyu Lee, Doyong Jeon, Seung Ryel Baek, Kim Joo Il, Kyoungjune Lee, Youn Soo Lee, Jin-Hyoung Kang
Publikováno v:
Cancer Research. 83:2232-2232
Introduction: Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations (mEGFR) well respond to EGFR TKIs, but the majority of patients eventually acquire drug resistance, leading to treatment failure. Recently, intracellular potenti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8680032ebf4c0bf22ed3fb366bc20100
https://doi.org/10.1158/1538-7445.am2023-2232
https://doi.org/10.1158/1538-7445.am2023-2232
Autor:
Jung-Young Shin, Min-Young Kim, Mi-Ran Lee, Hankyu Lee, Doyong Jeon, Seung Ryel Baek, Kim Joo Il, Jaemoon Koh, Dooil Jeoung, Jin Hyoung Kang
Publikováno v:
Cancer Research. 83:1582-1582
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is the standard of care as 1st-line treatment for NSCLC patients with activating EGFR mutations (exon 19 deletion or L858R mutation). However, EGFR-TKI therapy eventually leads to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a33dd28dfae7cfc723c73fc648b4167d
https://doi.org/10.1158/1538-7445.am2023-1582
https://doi.org/10.1158/1538-7445.am2023-1582
Autor:
Kyoung-Hwa Son, Jeong-Oh Kim, Chan Kwon Jung, Min Young Kim, Yeon Sil Kim, Jung-Young Shin, Jin-Hyoung Kang
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-14 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-14 (2020)
BackgroundHypoxic tumors are known to be highly resistant to radiotherapy and cause poor prognosis in non-small cell lung cancer (NSCLC) patients. CKD-516, a novel vascular disrupting agent (VDA), mainly affects blood vessels in the central area of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::112b152d95cfc33cb02ee47572d08666
http://europepmc.org/articles/PMC7607852
http://europepmc.org/articles/PMC7607852
Autor:
Jin Hyoung Kang, Sook Hee Hong, Yonggoo Kim, Kab Soo Shin, Joori Kim, Myungshin Kim, Min Young Kim, Seo Ree Kim, Jung-Young Shin, Mi-Ran Lee, Jeong-Oh Kim
Publikováno v:
Cancers
Cancers, Vol 12, Iss 4, p 785 (2020)
Cancers, Vol 12, Iss 4, p 785 (2020)
Epidermal growth factor receptor (EGFR) mutation testing is essential for individualized treatment using tyrosine kinase inhibitors. We evaluated two EGFR mutation tests, cobas v2 and PANAMutyper, for detection of EGFR activating mutations Ex19del, L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a607bdd8df1c10671f1d033ea5d81d9d
http://europepmc.org/articles/PMC7226165
http://europepmc.org/articles/PMC7226165
Autor:
Kim, Min-Young, Jung-Young Shin, Jeong-Oh Kim, Kyoung-Hwa Son, Kim, Yeon Sil, Jung, Chan Kwon, Jin-Hyoung Kang
Additional file 2. Toxicity of low- or high-dose IR in BALB/c nude mice. (A) The shielding device was made of 4 mm thick lead. The anesthetized mice were fixed in a 50 mL tube and irradiated with a lead shield. (B) Tumor growth and (C) body weight ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24940c8a33d2963cecd39be247097072
Autor:
Kim, Min-Young, Jung-Young Shin, Jeong-Oh Kim, Kyoung-Hwa Son, Kim, Yeon Sil, Jung, Chan Kwon, Jin-Hyoung Kang
Additional file 1. Short-term and long-term drug administration schedules.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::716f8bb188fa0f0528f63e3dadcf62f7
Autor:
Kim, Min-Young, Jung-Young Shin, Jeong-Oh Kim, Kyoung-Hwa Son, Kim, Yeon Sil, Jung, Chan Kwon, Jin-Hyoung Kang
Additional file 3. IHC staining with HIF-1α, VEGF, Glut-1, and Ki-67 antibodies in all five treatment groups (72 h after the end of treatment). Mice were divided into five groups according to the dosing and treatment schedule: vehicle (PBS), IR alon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ae1dfe1836d3971194e47a14ba47226
Autor:
Sang Ju Bae, Jung Young Shin, Jeong Oh Kim, Kyoung Hwa Son, Hyun Jung Min, Chan Kwon Jung, Tae-Jung Kim, Sook Whan Sung, Jin Hyoung Kang, Su Young Kim, Min Young Kim, Jae Kil Park
Publikováno v:
Surgical Oncology. 27:106-113
Background We screened resected tumor tissues from patients with lung cancer for EGFR mutations, ALK rearrangements, and rearranged during transfection (RET) gene variants (including RET rearrangements and the Kinesin Family Member 5B (KIF5B)-RET fus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d7a9a89093b720fc5ad1679e26f2655
https://doi.org/10.1016/j.suronc.2018.01.006
https://doi.org/10.1016/j.suronc.2018.01.006